Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Cormedix Inc's Business Segments
Cormedix Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
5
Largest Segment
Product
Total Revenue
$ 102
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product0%
- Defen Cath0%
- Melinta Portfolio51.6%
- Contract revenue7.9%
- Grant Income5%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 216 | - |
| Defen Cath | $ 164 | - |
| Melinta Portfolio | $ 53 | 51.6% |
2 more segments available
Sign in to unlock the full Cormedix Inc dataset.
Revenue by Product & Service Category - FY
- Product0%
- Defen Cath83.3%
- Melinta Portfolio20.8%
- Contract revenue4.7%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 122 | - |
| Defen Cath | $ 98 | 83.3% |
| Melinta Portfolio | $ 24 | 20.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Cormedix Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Product0%
- Defen Cath0%
- Melinta Portfolio51.6%
- Contract revenue7.9%
- Grant Income5%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 216 | - |
| Defen Cath | $ 164 | - |
| Melinta Portfolio | $ 53 | 51.6% |
2 more segments available
Sign in to unlock the full Cormedix Inc dataset.
Description of Cormedix Inc
Cormedix Inc is a publicly traded pharmaceutical company based in Berkeley Heights, New Jersey, USA. The company was founded in 2006 by Dr. Ira Marks, a physician and medical researcher with over 25 years of clinical and drug development experience. Cormedix is dedicated to developing and commercializing innovative products for the prevention and treatment of infectious and inflammatory diseases.
Cormedix's flagship product is Neutrolin, a catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs) in hemodialysis patients. Neutrolin is a combination of three active ingredients: taurolidine, citrate, and heparin. Taurolidine is a broad-spectrum antimicrobial agent that kills bacteria, fungi, and viruses. Citrate is a potent anticoagulant that inhibits the formation of blood clots. Heparin is a common anticoagulant that prevents the formation of fibrin clots.
Neutrolin is currently undergoing phase 3 clinical trials in the USA and Europe. The results of the phase 2 trial were very positive, with a 70% reduction in CRBSIs compared to standard of care. The phase 3 trials are expected to be completed in 2021, and Cormedix plans to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) shortly thereafter. Neutrolin has received fast-track designation from the FDA, meaning that it will receive expedited review and approval.
Cormedix has a strong pipeline of other potential products, including a combination product for the treatment of diabetic foot infections and a taurolidine-based nasal spray for the prevention of COVID-19. The company has also developed a proprietary technology platform called the Hampden system, which uses microfluidics to simulate human physiology and disease. The Hampden system allows for rapid and cost-effective preclinical testing of new drug candidates.
Cormedix has a talented and experienced management team, including CEO Khoso Baluch, CFO Richard M. Cohen, and CMO Nahar Zaidi. The company has a market capitalization of approximately $135 million and is listed on the NASDAQ exchange under the ticker symbol CRMD. Cormedix has partnerships with several leading academic and research institutions, including the University of Toronto, the Mayo Clinic, and the University of California, San Francisco. The company is well-positioned to deliver innovative solutions to major unmet medical needs.
Cormedix's flagship product is Neutrolin, a catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs) in hemodialysis patients. Neutrolin is a combination of three active ingredients: taurolidine, citrate, and heparin. Taurolidine is a broad-spectrum antimicrobial agent that kills bacteria, fungi, and viruses. Citrate is a potent anticoagulant that inhibits the formation of blood clots. Heparin is a common anticoagulant that prevents the formation of fibrin clots.
Neutrolin is currently undergoing phase 3 clinical trials in the USA and Europe. The results of the phase 2 trial were very positive, with a 70% reduction in CRBSIs compared to standard of care. The phase 3 trials are expected to be completed in 2021, and Cormedix plans to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) shortly thereafter. Neutrolin has received fast-track designation from the FDA, meaning that it will receive expedited review and approval.
Cormedix has a strong pipeline of other potential products, including a combination product for the treatment of diabetic foot infections and a taurolidine-based nasal spray for the prevention of COVID-19. The company has also developed a proprietary technology platform called the Hampden system, which uses microfluidics to simulate human physiology and disease. The Hampden system allows for rapid and cost-effective preclinical testing of new drug candidates.
Cormedix has a talented and experienced management team, including CEO Khoso Baluch, CFO Richard M. Cohen, and CMO Nahar Zaidi. The company has a market capitalization of approximately $135 million and is listed on the NASDAQ exchange under the ticker symbol CRMD. Cormedix has partnerships with several leading academic and research institutions, including the University of Toronto, the Mayo Clinic, and the University of California, San Francisco. The company is well-positioned to deliver innovative solutions to major unmet medical needs.
Cormedix Inc. operates within the pharmaceutical industry, emphasizing the development and commercialization of innovative anti-infective products. The company’s activities can be categorized into two primary segments: Development and Commercialization.
Segments
Development
The Development segment is dedicated to the research and development of Cormedixs pipeline of anti-infective products. It plays a crucial role in formulating unique therapeutic solutions aimed at effectively treating infectious diseases. The team is primarily focused on the advancement of Neutrolin, an innovative antimicrobial solution designed to mitigate the risk of bloodstream infections in patients undergoing hemodialysis, particularly those with central venous catheters and other vascular access devices. This segment encompasses various stages of clinical trials, regulatory submissions, and preclinical research efforts to ensure the safety, efficacy, and market readiness of Neutrolin and future product candidates.
Commercialization
The Commercialization segment is responsible for the market introduction and sales of Neutrolin. This segment is crucial for translating research results into clinical practice by establishing distribution partnerships and marketing strategies to facilitate the global reach of Neutrolin. Cormedix collaborates with numerous global distributors to ensure that the product is accessible in diverse regions, contributing to improved patient outcomes regarding catheter-related bloodstream infections (CRBSIs). The commercialization strategy includes market analysis, promotional activities, and working closely with healthcare providers to facilitate adoption.
Products and Services
Main Product: Neutrolin
Cormedixs flagship product, Neutrolin, is a patented antimicrobial solution formulated to prevent CRBSIs in patients undergoing hemodialysis. The formulation comprises taurolidine, citrate, and heparin, combining their beneficial properties to deliver a synergistic effect in infection prevention. Neutrolin aims to improve patient safety and outcomes by reducing the incidence of infections associated with vascular access devices, thereby shortening hospital stays and improving overall healthcare efficiency. The company is actively pursuing regulatory approvals needed to market Neutrolin in major international markets, including the U.S. Europe, and Asia.
Supportive Products
Cormedix also provides a range of supportive products that enhance the clinical utility of Neutrolin. These include:
- Diagnostic Tests: Cormedix offers various diagnostic solutions that provide healthcare providers with essential information regarding a patients infection status. These tests are designed to deliver actionable insights, enabling clinicians to make informed decisions regarding treatment protocols and optimize patient care.
- Therapeutic Solutions: In addition to Neutrolin, the company may offer complementary therapeutic products that work in conjunction with the antimicrobial solution to provide holistic patient management strategies.
Training and Education
Recognizing the importance of proper application and understanding of its products, Cormedix invests in comprehensive training and educational programs. These initiatives are designed for healthcare professionals, including nurses and physicians, to ensure they are knowledgeable about:
- The appropriate use of Neutrolin
- Patient selection criteria
- Administration techniques
The educational materials and training sessions help healthcare staff understand the best practices in the use of Neutrolin, thus ensuring a higher level of care for patients and improving clinical outcomes.
Conclusion
In summary, Cormedix Inc. is dedicated to developing and commercializing innovative anti-infective products, with Neutrolin at the forefront of its product lineup. By focusing on both the research and commercialization aspects, as well as providing supportive products and education, Cormedix aims to significantly enhance patient safety and infection management in healthcare settings worldwide. The company is committed to delivering high-quality products and services that benefits healthcare professionals and patients globally.
Segments
Development
The Development segment is dedicated to the research and development of Cormedixs pipeline of anti-infective products. It plays a crucial role in formulating unique therapeutic solutions aimed at effectively treating infectious diseases. The team is primarily focused on the advancement of Neutrolin, an innovative antimicrobial solution designed to mitigate the risk of bloodstream infections in patients undergoing hemodialysis, particularly those with central venous catheters and other vascular access devices. This segment encompasses various stages of clinical trials, regulatory submissions, and preclinical research efforts to ensure the safety, efficacy, and market readiness of Neutrolin and future product candidates.
Commercialization
The Commercialization segment is responsible for the market introduction and sales of Neutrolin. This segment is crucial for translating research results into clinical practice by establishing distribution partnerships and marketing strategies to facilitate the global reach of Neutrolin. Cormedix collaborates with numerous global distributors to ensure that the product is accessible in diverse regions, contributing to improved patient outcomes regarding catheter-related bloodstream infections (CRBSIs). The commercialization strategy includes market analysis, promotional activities, and working closely with healthcare providers to facilitate adoption.
Products and Services
Main Product: Neutrolin
Cormedixs flagship product, Neutrolin, is a patented antimicrobial solution formulated to prevent CRBSIs in patients undergoing hemodialysis. The formulation comprises taurolidine, citrate, and heparin, combining their beneficial properties to deliver a synergistic effect in infection prevention. Neutrolin aims to improve patient safety and outcomes by reducing the incidence of infections associated with vascular access devices, thereby shortening hospital stays and improving overall healthcare efficiency. The company is actively pursuing regulatory approvals needed to market Neutrolin in major international markets, including the U.S. Europe, and Asia.
Supportive Products
Cormedix also provides a range of supportive products that enhance the clinical utility of Neutrolin. These include:
- Diagnostic Tests: Cormedix offers various diagnostic solutions that provide healthcare providers with essential information regarding a patients infection status. These tests are designed to deliver actionable insights, enabling clinicians to make informed decisions regarding treatment protocols and optimize patient care.
- Therapeutic Solutions: In addition to Neutrolin, the company may offer complementary therapeutic products that work in conjunction with the antimicrobial solution to provide holistic patient management strategies.
Training and Education
Recognizing the importance of proper application and understanding of its products, Cormedix invests in comprehensive training and educational programs. These initiatives are designed for healthcare professionals, including nurses and physicians, to ensure they are knowledgeable about:
- The appropriate use of Neutrolin
- Patient selection criteria
- Administration techniques
The educational materials and training sessions help healthcare staff understand the best practices in the use of Neutrolin, thus ensuring a higher level of care for patients and improving clinical outcomes.
Conclusion
In summary, Cormedix Inc. is dedicated to developing and commercializing innovative anti-infective products, with Neutrolin at the forefront of its product lineup. By focusing on both the research and commercialization aspects, as well as providing supportive products and education, Cormedix aims to significantly enhance patient safety and infection management in healthcare settings worldwide. The company is committed to delivering high-quality products and services that benefits healthcare professionals and patients globally.